Inspiremd announces senior leadership changes to support commercial growth initiatives

Announces hiring of patrick verta, md, as executive vp of clinical and medical affairs cheryl tal joins as vp of quality assurance and regulatory affairs shane gleason, current general manager of north america & vp of global marketing, promoted to chief commercial officer reports inducement grant under nasdaq listing rule 5635(c)(4) tel aviv, israel and miami, oct. 03, 2023 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced senior leadership additions and changes intended to support the company's commercial growth initiatives, including potential approval of the cguard prime stent platform in the u.s., development of new stent delivery systems, and growth in existing approved territories outside of the u.s. the company announced today that it has hired patrick verta, md, as executive vice president of clinical and medical affairs and cheryl tal as vice president of quality assurance and regulatory affairs. in addition, shane gleason, who previously served as inspiremd's general manager of north america and vp of global marketing, has been promoted to chief commercial officer.
NSPR Ratings Summary
NSPR Quant Ranking